PDCD1 and neoplasm: In recent years, some studies have shown that CTLA-4 does not act like traditional immune checkpoints in anti-malignant tumor therapy such as PD-1 but rather activates immunity by clearing regulatory T cells in the tumor microenvironment (54–57).